Silo Pharma(US:SILO) Globenewswireยท2025-09-16 12:11Core Insights - The company has initiated its cryptocurrency treasury strategy by purchasing Ethereum (ETH) and Solana (SOL) tokens, marking a significant step towards integrating digital assets into its treasury holdings [2][3] - This investment reflects the company's belief in the long-term value of digital assets and the potential of blockchain technology to influence the biotechnology sector [2][3] - The CEO emphasized the company's commitment to decentralized finance and smart contract platforms, stating that the tokens will be staked for revenue generation and capital appreciation to support biopharmaceutical asset development [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4] - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories [4] Strategic Initiatives - The company's cryptocurrency treasury strategy aims for multi-chain asset growth and lays the groundwork for broader blockchain and real-world asset tokenization initiatives [2] - The accelerating adoption of digital assets by institutional investors and global enterprises supports the company's comprehensive digital assets strategy [3]